Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials
By the time I finished my last injection over the course of three months, I was up to 1.50 mg (the highest approved by the FDA is 2.4 mgs)
doi: 10.1016/j.therap.2020.06.012 13 DanserA
Data from the Danish DANHEP registry similarly demonstrated that CHB patients with cardiometabolic disorders experience higher rates of early liver complications compared with those without such conditions, underscoring the substantial burden of metabolic comorbidity in European HBV populations (95)
#DiabetesCare #PrecisionMedicine #MetabolicHealth #LowerTheDose #HealthcareInnovation To view or add a comment, sign in In our recent publication in Diabetes, Obesity and Metabolism, together with Professors Kokkinos and le Roux, we articulate a perspective grounded in robust scientific evidence, yet one that is rarely expressed with candor in the public scientific discourse: that, as with any other chronic disease, pharmacotherapy should constitute the central pillar in the treatment of obesity, while other approaches retain an important but complementary role